STOCKS | Zhaoyan New Drug Warns of Overheated Sentiment and Irrational Speculation Risk

Zhaoyan New Drug said its stock rose sharply over three straight trading days from July 14 to July 16, 2026, with the cumulative deviation in closing-price gains exceeding 20%. According to Jin10, the company warned that short-term gains had been large, market sentiment may be overheated, and irrational speculation risk remained high, with the stock facing a risk of decline at any time. The company also said the fair value of its biological assets was affected by multiple uncertainties and carried a significant risk of value fluctuations.